27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- Novo Nordisk A/S (NYSE:NVO) Q2 sales increased 10% Y/Y (17% at CER) to DKK 33.04 billion.
- Sales in International Operations increased 13% (17% CER) at DKK18.2 billion, and sales in North America Operations increased by 7% (16% at CER) to DKK14.8 billion.
- The gross margin contracted to 83.2% from 84.1% a year ago, with the operating margin decreased from 46.1% to 44.7%.
- Sales within Diabetes and Obesity care increased by 17% at CER to DKK 28.0 billion, driven by GLP-1 growth of 37% at CER, reflecting the uptake of Ozempic and Rybelsus.
- In June 2021, Wegovy, semaglutide 2.4 mg, was made available to U.S. patients following the FDA's approval for weight management in adults living with obesity.
- Net profit increased 14.1% Y/Y to DKK 12.1 billion, with EPS of DKK 5.26.
- FY21 Outlook: Novo Nordisk expects sales growth of 10%-13% at CER (previously 6%-10%) and operating profit growth of 9-12% at CER (formerly 5-9%).
- Price Action: NVO shares are up 5.60% at $97.08 during the market session on the last check Wednesday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!